CORT Valuation

Corcept Therapeutics Inc

Add to Watchlist

Advanced Chart

70.330

-0.65(-0.916%)1D

Overview
Forecast
Valuation
Earnings

CORT Relative Valuation

CORT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CORT is overvalued; if below, it's undervalued.

Historical Valuation

Corcept Therapeutics Inc (CORT) is now in the Overvalued zone, suggesting that its current forward PE ratio of 54.18 is considered Overvalued compared with the five-year average of 28.89. The fair price of Corcept Therapeutics Inc (CORT) is between 31.34 to 48.19 according to relative valuation methord. Compared to the current price of 70.33 USD , Corcept Therapeutics Inc is Overvalued By 45.95%.

Relative Value

Fair Zone

31.34-48.19

Current Price：70.33

45.95%

Overvalued

54.18

Trailing

Forward

27.33

EV/EBITDA

Corcept Therapeutics Inc. (CORT) has a current EV/EBITDA of 27.33. The 5-year average EV/EBITDA is 18.15. The thresholds are as follows: Strongly Undervalued below 6.33, Undervalued between 6.33 and 12.24, Fairly Valued between 24.07 and 12.24, Overvalued between 24.07 and 29.98, and Strongly Overvalued above 29.98. The current Forward EV/EBITDA of 27.33 falls within the Overvalued range.

44.19

EV/EBIT

Corcept Therapeutics Inc. (CORT) has a current EV/EBIT of 44.19. The 5-year average EV/EBIT is 18.94. The thresholds are as follows: Strongly Undervalued below 4.56, Undervalued between 4.56 and 11.75, Fairly Valued between 26.13 and 11.75, Overvalued between 26.13 and 33.33, and Strongly Overvalued above 33.33. The current Forward EV/EBIT of 44.19 falls within the Strongly Overvalued range.

7.22

Corcept Therapeutics Inc. (CORT) has a current PS of 7.22. The 5-year average PS is 5.98. The thresholds are as follows: Strongly Undervalued below 3.35, Undervalued between 3.35 and 4.67, Fairly Valued between 7.30 and 4.67, Overvalued between 7.30 and 8.61, and Strongly Overvalued above 8.61. The current Forward PS of 7.22 falls within the Historic Trend Line -Fairly Valued range.

39.78

P/OCF

Corcept Therapeutics Inc. (CORT) has a current P/OCF of 39.78. The 5-year average P/OCF is 18.55. The thresholds are as follows: Strongly Undervalued below 6.83, Undervalued between 6.83 and 12.69, Fairly Valued between 24.40 and 12.69, Overvalued between 24.40 and 30.26, and Strongly Overvalued above 30.26. The current Forward P/OCF of 39.78 falls within the Strongly Overvalued range.

39.84

P/FCF

Corcept Therapeutics Inc. (CORT) has a current P/FCF of 39.84. The 5-year average P/FCF is 19.75. The thresholds are as follows: Strongly Undervalued below 6.19, Undervalued between 6.19 and 12.97, Fairly Valued between 26.54 and 12.97, Overvalued between 26.54 and 33.32, and Strongly Overvalued above 33.32. The current Forward P/FCF of 39.84 falls within the Strongly Overvalued range.

Corcept Therapeutics Inc (CORT) has a current Price-to-Book (P/B) ratio of 11.75. Compared to its 3-year average P/B ratio of 6.92 , the current P/B ratio is approximately 69.88% higher. Relative to its 5-year average P/B ratio of 6.26, the current P/B ratio is about 87.90% higher. Corcept Therapeutics Inc (CORT) has a Forward Free Cash Flow (FCF) yield of approximately 2.43%. Compared to its 3-year average FCF yield of 4.13%, the current FCF yield is approximately -41.21% lower. Relative to its 5-year average FCF yield of 5.07% , the current FCF yield is about -52.07% lower.

11.75

P/B

Median3y

6.92

Median5y

6.26

2.43

FCF Yield

Median3y

4.13

Median5y

5.07

Competitors Valuation Multiple

The average P/S ratio for CORT's competitors is 56.61, providing a benchmark for relative valuation. Corcept Therapeutics Inc Corp (CORT) exhibits a P/S ratio of 7.22, which is -87.25% above the industry average. Given its robust revenue growth of 18.70%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CORT.O

Corcept Therapeutics Inc

Jazz Pharmaceuticals PLC

Ionis Pharmaceuticals Inc

Loss

100.69%

6.80B

Performance Decomposition

Market capitalization of CORT increased by 99.24% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 32.31 to 63.69.

The secondary factor is the Revenue Growth, contributed 18.70%to the performance.

Overall, the performance of CORT in the past 1 year is driven by P/E Change. Which is more unsustainable.

18.70%

163.80M → 194.43M

Revenue Growth

-16.57%

21.67 → 18.08

Margin Expansion

97.11%

32.31 → 63.69

P/E Change

99.24%